Daiichi Sankyo Company, Limited4568
▲ PositiveRegulationrelevance
Enhertu, co-developed with AstraZeneca, gained NHS England approval for HER2-low metastatic breast cancer, expanding access to the drug.
Impact on assets 2
Biotech & Genomic Medicine▲ · 2 stocks
Daiichi Sankyo Company, Limited
AstraZeneca PLCAZN
▲ PositiveRegulationrelevance
NICE reversed its rejection and approved NHS funding for Enhertu in HER2-low metastatic breast cancer, expanding access in England.
Theme Impact 2
Off-coverage companies
Related news
VERAXA Biotech Enters Next Phase After NASDAQ Listing and BiTAC Milestones
VERAXA Biotech is entering a new phase of development following its transition to the NASDAQ market and a series of scientific and corporate milestones centered on its proprietary BiTAC platform. The Swiss biotechnology company began trading on the NASDAQ Capital Market under the ticker VRXA in June following the completion of its business combination with Voyager Acquisition Corp. The transaction was accompanied by financing arrangements that included a $27.5 million senior secured note and a securities purchase agreement for up to an undisclosed additional amount. VERAXA is advancing an oncology pipeline built around BiTAC, an AND-gated therapeutic approach in which two complementary components must engage the same cancer cell before the intended cytotoxic mechanism is activated, alongside additional antibody-drug conjugate and engineered-antibody technologies. The company has reported early preclinical evidence for both its BiTAC-TCE and BiTAC-ADC approaches, including an in-vitro proof of concept for BiTAC-ADC announced in June, and recently appointed Raju Willener as CFO and Christoph Erkel, Ph.D., as chief scientific officer.
▲impact 4
China Sets 2030 Goal to Develop 25% of Global First-in-Class Drugs
Beijing has unveiled a five-year plan aimed at making China a global leader in drug innovation, with a target of developing 25% of the world's first-in-class drugs by 2030. The plan, issued in a joint notice from multiple government ministries, lays out 25 priority tasks spanning innovation capacity, research and technology, including expanded R&D, the use of AI and quantum computing in drug discovery, and the building of pharmaceutical ecosystems beyond pipelines. The government aims for the industry to reach 3.5tn yuan, or $520bn, in annual revenue by 2030, with 50 companies exceeding $1.5bn in annual revenue, and at least five Chinese drugs achieving global annual sales above $1bn. The notice singled out next-generation therapies including antibody-drug conjugates, cell and gene therapies, and CAR-T, along with vaccines and newer platforms such as mRNA, and included a section on industrialising traditional Chinese medicine. Citi analysts said the plan signals a shift from scale-driven growth toward innovation-driven, quality-oriented development, with a broad whole-value-chain policy push covering innovative drugs, medical devices, AI-driven drug discovery, and CDMO/CRO. The biomedical plan was released alongside counterparts for other strategic sectors, including integrated circuits, aerospace, the low-altitude economy, new energy storage and intelligent robotics.
▲3
Merck Wins CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
Merck announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of Keytruda in combination with Pfizer's Padcev for an expanded bladder cancer indication. The CHMP recommended Keytruda and its subcutaneous formulation, Keytruda Qlex, each in combination with Padcev as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment in adult patients with resectable muscle-invasive bladder cancer. The opinion was based on data from the phase III KEYNOTE-B15 study, conducted in collaboration with Pfizer and Astellas, and will now be reviewed by the European Commission, with a final decision expected in the fourth quarter of 2026. If approved, the regimen would become the first and only PD-1 inhibitor plus antibody-drug conjugate combination approved for patients with muscle-invasive bladder cancer regardless of cisplatin eligibility in Europe. The same regimen was approved by the FDA for the same indication in July 2026, while a separate cisplatin-ineligible MIBC approval was granted by the European Commission in June 2026 based on the phase III KEYNOTE-905 study. Keytruda generated $16.40 billion in sales in the first half of 2026, up 4.2% year over year, while Padcev, added from the December 2023 Seagen acquisition, generated $1.26 billion in the first half of 2026, up 30% year over year.